Coronavirus disease 2019 (Covid-19) vaccination recommendations in special populations and patients with existing comorbidities

Zeinab Mohseni Afshar, Arefeh Babazadeh, Alireza Janbakhsh, Feizollah Mansouri, Terence T. Sio, Mark J.M. Sullman, Kristin Carson-Chahhoud, Rezvan Hosseinzadeh, Mohammad Barary, Soheil Ebrahimpour

Research output: Contribution to journalReview articlepeer-review

Abstract

Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a crucial step in ending the current worldwide pandemic. However, several particularly vulnerable groups in the population were not included in sufficient numbers in coronavirus disease 2019 (Covid-19) vaccine trials. Therefore, as science advances, the advice for vaccinating these special populations against Covid-19 will continue to evolve. This focused review provides the latest recommendations and considerations for these special populations (i.e., patients with rheumatologic and autoimmune disorders, cancer, transplant recipients, chronic liver diseases, end-stage renal disease, neurologic disorders, psychiatric disorders, diabetes mellitus, obesity, cardiovascular diseases, chronic obstructive pulmonary disease, human immunodeficiency virus, current smokers, pregnant and breastfeeding women, the elderly, children, and patients with allergic reactions) using the currently available research evidence.

Original languageEnglish
JournalReviews in Medical Virology
DOIs
Publication statusAccepted/In press - 2021

Keywords

  • Covid-19
  • efficacy
  • immunocompromise
  • safety
  • SARS-CoV-2
  • vaccination

Fingerprint

Dive into the research topics of 'Coronavirus disease 2019 (Covid-19) vaccination recommendations in special populations and patients with existing comorbidities'. Together they form a unique fingerprint.

Cite this